126 related articles for article (PubMed ID: 7598233)
1. Male reproductive potential after MOPP therapy for Hodgkin's disease: a long-term survey.
Marmor D; Duyck F
Andrologia; 1995; 27(2):99-106. PubMed ID: 7598233
[TBL] [Abstract][Full Text] [Related]
2. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
[TBL] [Abstract][Full Text] [Related]
3. Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy.
da Cunha MF; Meistrich ML; Fuller LM; Cundiff JH; Hagemeister FB; Velasquez WS; McLaughlin P; Riggs SA; Cabanillas FF; Salvador PG
J Clin Oncol; 1984 Jun; 2(6):571-7. PubMed ID: 6547167
[TBL] [Abstract][Full Text] [Related]
4. Testicular dysfunction in Hodgkin's disease before and after treatment.
Viviani S; Ragni G; Santoro A; Perotti L; Caccamo E; Negretti E; Valagussa P; Bonadonna G
Eur J Cancer; 1991; 27(11):1389-92. PubMed ID: 1835853
[TBL] [Abstract][Full Text] [Related]
5. Gonadal function following ABVD therapy for Hodgkin's disease.
Kulkarni SS; Sastry PS; Saikia TK; Parikh PM; Gopal R; Advani SH
Am J Clin Oncol; 1997 Aug; 20(4):354-7. PubMed ID: 9256888
[TBL] [Abstract][Full Text] [Related]
6. Inhibin B is superior to FSH as a serum marker for spermatogenesis in men treated for Hodgkin's lymphoma with chemotherapy during childhood.
van Beek RD; Smit M; van den Heuvel-Eibrink MM; de Jong FH; Hakvoort-Cammel FG; van den Bos C; van den Berg H; Weber RF; Pieters R; de Muinck Keizer-Schrama SM
Hum Reprod; 2007 Dec; 22(12):3215-22. PubMed ID: 17981817
[TBL] [Abstract][Full Text] [Related]
7. Testicular function after combination chemotherapy for Hodgkin's disease.
Asbjornsen G; Molne K; Klepp O; Aakvaag A
Scand J Haematol; 1976 Jan; 16(1):66-9. PubMed ID: 1251141
[TBL] [Abstract][Full Text] [Related]
8. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD.
Viviani S; Santoro A; Ragni G; Bonfante V; Bestetti O; Bonadonna G
Eur J Cancer Clin Oncol; 1985 May; 21(5):601-5. PubMed ID: 2408897
[TBL] [Abstract][Full Text] [Related]
9. The effects of etoposide on testicular function in boys treated for Hodgkin's disease.
Gerres L; Brämswig JH; Schlegel W; Jürgens H; Schellong G
Cancer; 1998 Nov; 83(10):2217-22. PubMed ID: 9827728
[TBL] [Abstract][Full Text] [Related]
10. Gonadal function and fertility in male survivors treated for Hodgkin's disease in Iran.
Rafsanjani KA; Faranoush M; Hedayatiasl AA; Vossough P
Saudi Med J; 2007 Nov; 28(11):1690-3. PubMed ID: 17965791
[TBL] [Abstract][Full Text] [Related]
11. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease.
Meistrich ML; Wilson G; Mathur K; Fuller LM; Rodriguez MA; McLaughlin P; Romaguera JE; Cabanillas FF; Ha CS; Lipshultz LI; Hagemeister FB
J Clin Oncol; 1997 Dec; 15(12):3488-95. PubMed ID: 9396402
[TBL] [Abstract][Full Text] [Related]
12. [Changes in gonadal function in post-pubertal male survivors of acute lymphoblastic leukemia and Hodgkin's disease].
Soriano Guillén L; Muñoz Calvo MT; Pozo Román J; Contra Gómez T; Buño Soto M; Argente Oliver J
An Esp Pediatr; 2000 Oct; 53(4):318-23. PubMed ID: 11083980
[TBL] [Abstract][Full Text] [Related]
13. Decreasing the number of MOPP courses reduces gonadal damage in survivors of childhood Hodgkin disease.
van den Berg H; Furstner F; van den Bos C; Behrendt H
Pediatr Blood Cancer; 2004 Mar; 42(3):210-5. PubMed ID: 14752856
[TBL] [Abstract][Full Text] [Related]
14. Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy for Hodgkin's disease.
Kreuser ED; Xiros N; Hetzel WD; Heimpel H
J Cancer Res Clin Oncol; 1987; 113(3):260-6. PubMed ID: 3108263
[TBL] [Abstract][Full Text] [Related]
15. Irreversible gonadal damage in male survivors of pediatric Hodgkin's disease.
Heikens J; Behrendt H; Adriaanse R; Berghout A
Cancer; 1996 Nov; 78(9):2020-4. PubMed ID: 8909325
[TBL] [Abstract][Full Text] [Related]
16. Testicular function following the treatment of Hodgkin's disease in childhood.
Shafford EA; Kingston JE; Malpas JS; Plowman PN; Pritchard J; Savage MO; Eden OB
Br J Cancer; 1993 Dec; 68(6):1199-204. PubMed ID: 8260374
[TBL] [Abstract][Full Text] [Related]
17. Treatment with the gonadotropin-releasinghormone agonist buserelin to protect spermatogenesis against cytotoxic treatment in young men.
Krause W; Pflüger KH
Andrologia; 1989; 21(3):265-70. PubMed ID: 2476046
[TBL] [Abstract][Full Text] [Related]
18. Gonadal function following chemotherapy for Hodgkin's disease: a comparative study of MVPP and a seven-drug hybrid regimen.
Clark ST; Radford JA; Crowther D; Swindell R; Shalet SM
J Clin Oncol; 1995 Jan; 13(1):134-9. PubMed ID: 7799013
[TBL] [Abstract][Full Text] [Related]
19. Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: the Stanford experience.
Ortin TT; Shostak CA; Donaldson SS
Int J Radiat Oncol Biol Phys; 1990 Oct; 19(4):873-80. PubMed ID: 2211255
[TBL] [Abstract][Full Text] [Related]
20. The effects of different cumulative doses of chemotherapy on testicular function. Results in 75 patients treated for Hodgkin's disease during childhood or adolescence.
Brämswig JH; Heimes U; Heiermann E; Schlegel W; Nieschlag E; Schellong G
Cancer; 1990 Mar; 65(6):1298-302. PubMed ID: 2106384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
